Scientists have discovered that a small chemokine protein released by activated platelets, platelet factor 4 (PF 4), reduced neuroinflammation, and improved cognition in aged mice. The study was published on Aug. 16 in the online edition of Nature.
Researchers at 3D Medicines (Beijing) Co. Ltd. and 3D Medicines Inc. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.
Sichuan Good Doctor Panxi Pharmaceutical Co. Ltd. has identified polypeptides reported to be useful for the treatment of inflammatory bowel disease, ulcerative colitis, and dysbacteriosis.
Biogen Inc. has synthesized 3-β-hydroxysteroid-δ(8),δ(7)-isomerase (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis (MS).
Origenis GmbH has described cyclin-dependent kinase 9 (CDK9) inhibitors, particularly CDK9/cyclin T1, reported to be useful for the treatment of cancer, viral infections, obesity and more.
Leukemic cells rely on excessive mitochondrial respiratory and energy metabolism. Therefore, targeting mitochondrial proteases has been proposed as a potential approach to improve therapeutic regimens for acute myeloid leukemia (AML). The mitochondrial caseinolytic protease P (ClpP), located in the mitochondrial matrix, maintains protein quality by mediating the proteolytic hydrolysis of damaged proteins. The chaperone ClpX regulates this hydrolysis and is overexpressed in AML, thus providing a rationale for using ClpP agonists to disrupt AML proliferation.
Cytomed Therapeutics Ltd. has signed a memorandum of understanding (MOU) with Hangzhou CNK Therapeutics Co. Ltd. allowing Cytomed to utilize CNK's Piggybac technology to permanently graft the chimeric antigen receptor (CAR) gene into its γδ T cells via a non-viral gene editing method.
RSS
